Antoine Leuzy, PhD

Dr. Antoine Leuzy is a neuroimaging and biomarker expert focused on Alzheimer’s and related disorders. He earned his PhD in Medicine at Karolinska Institute, following an MSc at the Montreal Neurological Institute, where he worked on the development of novel PET tracers targeting amyloid and the glutamatergic system. His postdoctoral work at Lund University, industry funded by Roche, focused on the evaluation and quantitative analysis of a novel tau PET tracer, integrating longitudinal and multimodal approaches. Dr. Leuzy’s work spans blood-based biomarkers and longitudinal PET methods, including highly cited papers in EMBO Molecular Medicine on blood biomarkers, JAMA Neurology on predicting tau PET change and optimizing regions for longitudinal analyses, and Nature Communications on plasma biomarkers improving diagnostic accuracy. He is also active in translating methods and standards for clinical use, with recent contributions addressing practical considerations for amyloid PET and CSF biomarkers and realistic screening approaches for Alzheimer’s disease. He joined EBG in 2021 as a Clinical Imaging Scientist, applying biomarker science and advanced neuroimaging methods to clinical and industry research.